Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Hematology"
DOI: 10.1097/moh.0000000000000543
Abstract: PURPOSE OF REVIEW The current review aims to highlight recent and important developments in the detection and value of minimal (measurable) residual disease (MRD) testing in patients with acute myeloid leukemia (AML) and the impact… read more here.
Keywords: acute myeloid; residual disease; measurable residual; timing allogeneic ... See more keywords